U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H29FO5
Molecular Weight 392.4619
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXAMETHASONE

SMILES

C[C@]1([H])C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@]3([C@]([H])(C[C@]2(C)[C@]1(C(=O)CO)O)O)F

InChI

InChIKey=UREBDLICKHMUKA-CXSFZGCWSA-N
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

HIDE SMILES / InChI
Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune response. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
MAXIDEX

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

-237859200000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237859200000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-237772800000
Primary
Neofordex

Approved Use

Neofordex is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.

Launch Date

1458000000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.87 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
51.2 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.93 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
DEXAMETHASONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
96 mg multiple, oral
Dose: 96 mg
Route: oral
Route: multiple
Dose: 96 mg
Sources:
unhealthy, 63 years (range: 30–78 years)
Health Status: unhealthy
Age Group: 63 years (range: 30–78 years)
Sex: M+F
Sources:
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Sources:
Other AEs: Corneal erosion...
Other AEs:
Corneal erosion (10%)
Sources:
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
Other AEs: Constipation...
Other AEs:
Constipation (below serious, 1 patient)
Sources:
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Drowsiness, Dizziness...
Other AEs:
Drowsiness (below serious, 19 patients)
Dizziness (below serious, 3 patients)
Adverse drug reaction NOS (below serious, 10 patients)
Sources:
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Wound dehiscence...
Other AEs:
Wound dehiscence (below serious, 1 patient)
Sources:
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Dizziness...
Other AEs:
Dizziness (below serious, 1 patient)
Sources:
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Constipation, Dyspepsia...
Other AEs:
Constipation (below serious, 47 patients)
Dyspepsia (below serious, 12 patients)
Vomiting (below serious, 9 patients)
Fatigue (below serious, 58 patients)
Cholesterol high (below serious, 8 patients)
Anorexia (below serious, 15 patients)
Anxiety (below serious, 11 patient)
Insomnia (below serious, 26 patients)
Cough (below serious, 9 patients)
Dyspnea (below serious, 20 patients)
Sources:
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Other AEs: Incision site bleeding, Body temperature decrease...
Other AEs:
Incision site bleeding (below serious, 1 patient)
Body temperature decrease (below serious, 2 patients)
Shivering (below serious, 1 patient)
Tachycardia (below serious, 1 patient)
Transfusion (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Corneal erosion 10%
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Sources:
Constipation below serious, 1 patient
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
Adverse drug reaction NOS below serious, 10 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
Drowsiness below serious, 19 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness below serious, 3 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
Wound dehiscence below serious, 1 patient
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness below serious, 1 patient
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anxiety below serious, 11 patient
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspepsia below serious, 12 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anorexia below serious, 15 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspnea below serious, 20 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Insomnia below serious, 26 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Constipation below serious, 47 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fatigue below serious, 58 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cholesterol high below serious, 8 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cough below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vomiting below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Incision site bleeding below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Shivering below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Tachycardia below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Transfusion below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Body temperature decrease below serious, 2 patients
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: These data demonstrate that dexamethasone at doses used clinically increased CYP3A4 activity with extensive intersubject variability and that the extent of CYP3A4 induction was, in part, predicted by the baseline activity of CYP3A4 in both healthy volunteers and human hepatocyte cultures.
Page: -
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Effects of dexamethasone on tumor-induced brain edema and its distribution in the brain of monkeys.
1979 Mar
Regulation of RANTES and ICAM-1 expression in murine mesangial cells.
1997 Apr
Effect of antenatal glucocorticoid administration on insulin-like growth factor I and II levels in hypoplastic lung in nitrofen-induced congenital diaphragmatic hernia in rats.
1999
Functional assay of NF-kappaB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline.
1999 Apr
Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA.
1999 Aug 12
Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells.
1999 Dec
Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors.
1999 Dec 24
Inhibition of transforming growth factor beta1-induced hepatoma cell apoptosis by liver tumor promoters: characterization of primary signaling events and effects on CPP32-like caspase activity.
1999 Feb
Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
1999 Feb
Inhibition of gelatinase activity in human airway epithelial cells and fibroblasts by dexamethasone and beclomethasone.
1999 Jul
Platelet-activating factor receptor mRNA is localized in eosinophils and epithelial cells in rat small intestine: regulation by dexamethasone and gut flora.
1999 Jul
Structure, evolution, and liver-specific expression of sterol 12alpha-hydroxylase P450 (CYP8B).
1999 Jul
Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease.
1999 Jun
Differential regulation of peptide alpha-amidation by dexamethasone and disulfiram.
1999 Jun
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts.
1999 Jun
Pharmacological validation of a feline model of steroid-induced ocular hypertension.
1999 Mar
Neuroendocrine mediators up-regulate alpha1b- and alpha1d-adrenergic receptor subtypes in human monocytes.
1999 Mar 1
Intestinal damage induced by zinc deficiency is associated with enhanced CuZn superoxide dismutase activity in rats: effect of dexamethasone or thyroxine treatment.
1999 May
Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells.
1999 Nov
Dexamethasone therapy increases infection in very low birth weight infants.
1999 Nov
Antenatal dexamethasone suppresses tumor necrosis factor-alpha expression in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
1999 Nov
Dexamethasone increases eNOS gene expression and prevents renal vasoconstriction induced by cyclosporin.
1999 Sep
Melatonin regulates glucocorticoid receptor: an answer to its antiapoptotic action in thymus.
1999 Sep
Morphine induced allodynia in a child with brain tumour.
1999 Sep 4
Dexamethasone enhances ras-recision gene expression in cultured murine fetal lungs: role in development.
2000 Aug
Dexamethasone suppresses tumor necrosis factor-alpha-induced apoptosis in osteoblasts: possible role for ceramide.
2000 Aug
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
2000 Aug
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
2000 Aug 1
Suppressive effect of active hexose correlated compound (AHCC) on thymic apoptosis induced by dexamethasone in the rat.
2000 Dec
Prenatal exposure to high levels of glucocorticoids increases the susceptibility of cerebellar granule cells to oxidative stress-induced cell death.
2000 Dec 19
Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats.
2000 Feb
All-trans-retinoic acid-induced myositis: a description of two patients.
2000 Feb
Dexamethasone blocks sepsis-induced protection of the heart from ischemia reperfusion injury.
2000 Jan
Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review.
2000 Jul 29
Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing.
2000 Jun
Down-regulation of thyroid transcription factor-1 gene expression in fetal lung hypoplasia is restored by glucocorticoids.
2000 Jun
beta(3)-adrenoceptor regulation and relaxation responses in mouse ileum.
2000 Mar
Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line.
2000 Mar
Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone.
2000 May-Jun
Corticosteroids and cognitive function in humans: methodological considerations.
2000 May-Jun
Ocular hypertensive response to topical dexamethasone in children: a dose-dependent phenomenon.
2000 Nov
ECT administration in a patient after craniotomy and gamma knife surgery: a case report and review.
2000 Sep
Involvement of tyrosine hydroxylase up regulation in dexamethasone-induced hypertension of rats.
2000 Sep 8
Intractable nausea attributable to isolated deficiency of adrenocorticotropic hormone: prompt resolution after administration of glucocorticoid.
2000 Sep-Oct
A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide.
2001 Feb
Molecular and pharmacological evidence for modulation of kinin B(1) receptor expression by endogenous glucocorticoids hormones in rats.
2001 Jan
Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.
2001 Jan 11
Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs.
2012 Jun
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
2012 Jun
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
2012 Nov
Patents

Sample Use Guides

One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly. In
Route of Administration: Other
Caco-2 cells were treated with 1 μM dexamethasone and SGK1 mRNA levels were determined by Northern blot analysis. Figure 1A shows that dexamethasone rapidly induced SGK1 mRNA expression as early as 30 min and maintained the elevated expression for at least 24 h.
Name Type Language
DEXAMETHASONE
EMA EPAR   EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
ISV-305
Code English
DEXASONE
Brand Name English
DEXAMETHASONE [MART.]
Common Name English
DEXAMETHASONE [EP MONOGRAPH]
Common Name English
DEXAMETHASONE COMPONENT OF TOBRADEX ST
Brand Name English
DEXAMETHASONE [WHO-DD]
Common Name English
DEXAMETHASONE [ORANGE BOOK]
Common Name English
DEXAMETHASONE COMPONENT OF CIPRODEX
Brand Name English
DEXAMETHASONE [USP-RS]
Common Name English
LOVERINE
Brand Name English
GAMMACORTEN
Common Name English
DEXAMETASONE
Common Name English
MAXIDEX
Brand Name English
SUPERPREDNOL
Common Name English
FORTECORTIN
Brand Name English
DEXAMETHASONE ACETATE IMPURITY A [EP]
Common Name English
DEXASPORIN COMPONENT DEXAMETHASONE
Brand Name English
IMPURITY A [WHO-IP]
Common Name English
DEXAMETHASONE [JAN]
Common Name English
(11.BETA.,16.ALPHA.)-9-FLUORO-11,17,21-TRIHYDROXY-16-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Systematic Name English
DEXA-SINE
Brand Name English
DEXONE
Brand Name English
MAXITROL COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONUM [WHO-IP LATIN]
Common Name English
DEXAMETHASONE COMPONENT OF DEXASPORIN
Brand Name English
NSC-34521
Code English
DEXAMETHASONE [EMA EPAR]
Common Name English
FLUORMETHYLPREDNISOLONE
Common Name English
AEROSEB-DEX
Brand Name English
DEXAMETHASONE [INN]
Common Name English
DEXAMETHASONE COMPONENT OF DEXACIDIN
Brand Name English
BETAMETHASONE IMPURITY A [EP]
Common Name English
DEXASITE
Brand Name English
DEXAMONOZON
Brand Name English
DEXAMETHASONE COMPONENT OF TOBRADEX
Brand Name English
DEXAMETHASONE [VANDF]
Common Name English
DEXAPOS
Brand Name English
LUXAZONE
Brand Name English
DECADRON
Brand Name English
DEXYCU
Brand Name English
TOBRADEX ST COMPONENT DEXAMETHASONE
Brand Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,17,21-TRIHYDROXY-16-METHYL-,(11.BETA.,16.ALPHA.)-9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Common Name English
DEXACIDIN COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONE [WHO-IP]
Common Name English
TOBRADEX COMPONENT DEXAMETHASONE
Brand Name English
HEMADY
Brand Name English
HEXADROL
Brand Name English
DECADERM
Brand Name English
DEXAMETHASONE [USP MONOGRAPH]
Common Name English
OZURDEX
Brand Name English
ISOPTO-DEX
Brand Name English
CIPRODEX COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONE [HSDB]
Common Name English
DEXAMETHASONE [MI]
Common Name English
VISUMETAZONE
Common Name English
HEXADECADROL
Common Name English
DEXACORTAL
Brand Name English
9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Systematic Name English
DECASPRAY
Brand Name English
MILLICORTEN
Common Name English
DEXACORTIN
Brand Name English
DEXAMETHASONE COMPONENT OF MAXITROL
Brand Name English
DEXTENZA
Brand Name English
16.ALPHA.-METHYL-9.ALPHA.-FLUOROPREDNISOLONE
Common Name English
APHTHASOLONE
Common Name English
OTO-104
Code English
DEXAMETHASONE [GREEN BOOK]
Common Name English
Classification Tree Code System Code
WHO-ATC R01AD03
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.4
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 522.540
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 520.540
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 520.540A
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QD10AA03
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
FDA ORPHAN DRUG 674718
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S01BA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S03BA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC D07XB05
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QR01AD03
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QD07AB19
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QH02AB02
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 17.2
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
FDA ORPHAN DRUG 795620
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
NDF-RT N0000175576
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS01CB01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QD07XB05
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC C05AA09
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 520.540C
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC R01AD53
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
EMA ASSESSMENT REPORTS OZURDEX (AUTHORIZED: MACULAR EDEMA)
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS02BA06
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
EMA ASSESSMENT REPORTS ORZUDEX (AUTHORIZED: UVEITIS)
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QD07CB04
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S03CA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S02BA06
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS03CA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S01CA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS01BA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
FDA ORPHAN DRUG 115298
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S02CA06
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QR01AD53
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.3
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
LIVERTOX 288
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 522.542
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
NCI_THESAURUS C267
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS03BA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC D07AB19
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS01CA01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QC05AA09
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
NDF-RT N0000175450
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC S01CB01
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
EMA ASSESSMENT REPORTS NEOFORDEX (AUTHORIZED: MULTIPLE MYELOMA)
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC H02AB02
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QA01AC02
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 520.540B
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC A01AC02
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC D10AA03
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 03
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
EU-Orphan Drug EU/3/10/763
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 524.1484G
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QH02BX90
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
CFR 21 CFR 520.563
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
FDA ORPHAN DRUG 626318
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-ATC D07CB04
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
WHO-VATC QS02CA06
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
Code System Code Type Description
WIKIPEDIA
DEXAMETHASONE
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
PUBCHEM
5743
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
NCI_THESAURUS
C422
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
USP_CATALOG
1176007
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY USP-RS
LACTMED
Dexamethasone, Topical
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
HSDB
3053
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
MERCK INDEX
M4215
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY Merck Index
RXCUI
3264
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB01234
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DEXAMETHASONE
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY Description: Colourless crystals or a white or almost white, crystalline powder; odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS.Category: Adrenoglucocorticoid. Storage: Dexamethasone should be kept in a tightly closed container, protected from light.
LACTMED
Dexamethasone
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
DRUG CENTRAL
824
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
FDA UNII
7S5I7G3JQL
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
MESH
D003907
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
IUPHAR
2768
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
EPA CompTox
50-02-2
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-003-9
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
EVMPD
SUB07017MIG
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
CAS
50-02-2
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
ChEMBL
CHEMBL384467
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY
INN
816
Created by admin on Fri Jun 25 20:46:36 UTC 2021 , Edited by admin on Fri Jun 25 20:46:36 UTC 2021
PRIMARY